Raphael Pharmaceutical Gross Profit

The latest gross profit for RAPH is $-1K as of June 2026. In the prior-year period, the figure was $0. That is below the sector sector average of $6T. Investors often review this figure alongside Raphael Pharmaceutical's historical trend and sector peers before judging valuation or financial health.

Over the past year, RAPH's gross profit moved from $0 to $-1K. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Raphael Pharmaceutical's operating scale or balance-sheet position.

Against its sector companies, RAPH currently prints $-1K for gross profit, while the sector average sits near $6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Raphael Pharmaceutical's growth, margins, and balance sheet.

A gross profit figure of $-1K for RAPH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $6T. Explore the charts below for those layers of context.

After noting RAPH's gross profit ($-1K), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.